Annual CFO
-$51.16 M
-$19.53 M-61.74%
31 December 2023
Summary:
Cartesian Therapeutics annual cash flow from operations is currently -$51.16 million, with the most recent change of -$19.53 million (-61.74%) on 31 December 2023. During the last 3 years, it has fallen by -$86.04 million (-246.67%). RNAC annual CFO is now -246.67% below its all-time high of $34.88 million, reached on 01 December 2020.RNAC Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$13.69 M
+$28.14 M+194.77%
01 September 2024
Summary:
Cartesian Therapeutics quarterly cash flow from operations is currently $13.69 million, with the most recent change of +$28.14 million (+194.77%) on 01 September 2024. Over the past year, it has increased by +$22.91 million (+248.57%). RNAC quarterly CFO is now -79.14% below its all-time high of $65.64 million, reached on 01 September 2020.RNAC Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$39.96 M
+$22.91 M+36.44%
01 September 2024
Summary:
Cartesian Therapeutics TTM cash flow from operations is currently -$39.96 million, with the most recent change of +$22.91 million (+36.44%) on 01 September 2024. Over the past year, it has dropped by -$234.00 thousand (-0.59%). RNAC TTM CFO is now -199.37% below its all-time high of $40.21 million, reached on 01 June 2021.RNAC TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RNAC Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -61.7% | +248.6% | -0.6% |
| 3 y3 years | -246.7% | +227.4% | -10.5% |
| 5 y5 years | +13.5% | +223.1% | +22.1% |
RNAC Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -246.7% | +15.3% | at high | +143.5% | -52.8% | +39.8% |
| 5 y | 5 years | -246.7% | +15.3% | -79.1% | +143.5% | -199.4% | +39.8% |
| alltime | all time | -246.7% | +15.3% | -79.1% | +143.5% | -199.4% | +39.8% |
Cartesian Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $13.69 M(-194.8%) | -$39.96 M(-36.4%) |
| June 2024 | - | -$14.45 M(-9.2%) | -$62.86 M(+7.8%) |
| Mar 2024 | - | -$15.92 M(-31.6%) | -$58.31 M(+14.0%) |
| Dec 2023 | -$51.16 M(+61.7%) | -$23.29 M(+152.7%) | -$51.16 M(+28.8%) |
| Sept 2023 | - | -$9.21 M(-6.9%) | -$39.72 M(+51.9%) |
| June 2023 | - | -$9.89 M(+12.9%) | -$26.16 M(-8.3%) |
| Mar 2023 | - | -$8.77 M(-26.0%) | -$28.53 M(-9.8%) |
| Dec 2022 | -$31.63 M(-47.6%) | - | - |
| Dec 2022 | - | -$11.85 M(-372.2%) | -$31.63 M(-38.3%) |
| Sept 2022 | - | $4.35 M(-135.5%) | -$51.24 M(-22.8%) |
| June 2022 | - | -$12.27 M(+3.4%) | -$66.34 M(+10.4%) |
| Mar 2022 | - | -$11.86 M(-62.3%) | -$60.11 M(-0.4%) |
| Dec 2021 | -$60.38 M(-273.1%) | -$31.46 M(+192.8%) | -$60.38 M(+66.9%) |
| Sept 2021 | - | -$10.75 M(+77.8%) | -$36.17 M(-190.0%) |
| June 2021 | - | -$6.04 M(-50.2%) | $40.21 M(+16.7%) |
| Mar 2021 | - | -$12.13 M(+67.4%) | $34.45 M(-1.2%) |
| Dec 2020 | $34.88 M(-167.8%) | -$7.25 M(-111.0%) | $34.88 M(+19.2%) |
| Sept 2020 | - | $65.64 M(-655.9%) | $29.25 M(-161.6%) |
| June 2020 | - | -$11.81 M(+0.9%) | -$47.50 M(+10.8%) |
| Mar 2020 | - | -$11.70 M(-9.1%) | -$42.89 M(-16.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$51.44 M(-13.1%) | -$12.88 M(+15.8%) | -$51.44 M(+0.2%) |
| Sept 2019 | - | -$11.12 M(+54.5%) | -$51.31 M(-8.7%) |
| June 2019 | - | -$7.20 M(-64.4%) | -$56.22 M(-14.8%) |
| Mar 2019 | - | -$20.24 M(+58.8%) | -$65.99 M(+11.5%) |
| Dec 2018 | -$59.16 M(+13.7%) | -$12.75 M(-20.5%) | -$59.16 M(+0.1%) |
| Sept 2018 | - | -$16.03 M(-5.5%) | -$59.07 M(+1.0%) |
| June 2018 | - | -$16.97 M(+26.6%) | -$58.48 M(+16.7%) |
| Mar 2018 | - | -$13.41 M(+5.9%) | -$50.12 M(-3.7%) |
| Dec 2017 | -$52.03 M(+163.3%) | -$12.66 M(-18.0%) | -$52.03 M(+37.3%) |
| Sept 2017 | - | -$15.44 M(+79.2%) | -$37.88 M(+35.7%) |
| June 2017 | - | -$8.61 M(-43.8%) | -$27.91 M(+12.1%) |
| Mar 2017 | - | -$15.32 M(-1133.5%) | -$24.91 M(+26.1%) |
| Dec 2016 | -$19.76 M(-12.0%) | $1.48 M(-127.1%) | -$19.76 M(-31.6%) |
| Sept 2016 | - | -$5.47 M(-2.5%) | -$28.88 M(-0.5%) |
| June 2016 | - | -$5.61 M(-44.8%) | -$29.02 M(+4.7%) |
| Mar 2016 | - | -$10.17 M(+33.1%) | -$27.73 M(+23.5%) |
| Dec 2015 | -$22.46 M(+77.1%) | -$7.64 M(+36.1%) | -$22.46 M(+51.5%) |
| Sept 2015 | - | -$5.61 M(+30.1%) | -$14.82 M(+60.9%) |
| June 2015 | - | -$4.31 M(-11.9%) | -$9.21 M(+88.1%) |
| Mar 2015 | - | -$4.90 M | -$4.90 M |
| Dec 2014 | -$12.69 M | - | - |
FAQ
- What is Cartesian Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Cartesian Therapeutics?
- What is Cartesian Therapeutics annual CFO year-on-year change?
- What is Cartesian Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Cartesian Therapeutics?
- What is Cartesian Therapeutics quarterly CFO year-on-year change?
- What is Cartesian Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Cartesian Therapeutics?
- What is Cartesian Therapeutics TTM CFO year-on-year change?
What is Cartesian Therapeutics annual cash flow from operations?
The current annual CFO of RNAC is -$51.16 M
What is the all time high annual CFO for Cartesian Therapeutics?
Cartesian Therapeutics all-time high annual cash flow from operations is $34.88 M
What is Cartesian Therapeutics annual CFO year-on-year change?
Over the past year, RNAC annual cash flow from operations has changed by -$19.53 M (-61.74%)
What is Cartesian Therapeutics quarterly cash flow from operations?
The current quarterly CFO of RNAC is $13.69 M
What is the all time high quarterly CFO for Cartesian Therapeutics?
Cartesian Therapeutics all-time high quarterly cash flow from operations is $65.64 M
What is Cartesian Therapeutics quarterly CFO year-on-year change?
Over the past year, RNAC quarterly cash flow from operations has changed by +$22.91 M (+248.57%)
What is Cartesian Therapeutics TTM cash flow from operations?
The current TTM CFO of RNAC is -$39.96 M
What is the all time high TTM CFO for Cartesian Therapeutics?
Cartesian Therapeutics all-time high TTM cash flow from operations is $40.21 M
What is Cartesian Therapeutics TTM CFO year-on-year change?
Over the past year, RNAC TTM cash flow from operations has changed by -$234.00 K (-0.59%)